This article has been updated to clarify Alnylam's partnership with Medtronic and statements regarding its liver cancer program.

By Doug Macron

When Alnylam Pharmaceuticals announced last week its latest product-development strategy, it said it reflected a shift of its focus onto "genetically defined diseases" offering the potential for "early commercialization opportunities."

It also marked the latest in a series of pipeline changeups the company has undertaken since it was founded in 2002.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.